The Global Health Body Sounds Alert Over Acute Scarcity of Obesity Medications

Under 10% of people who could benefit from obesity jabs like Wegovy are able to get them, states the WHO as it releases its initial guidance on the drugs.

Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer access to these injectable treatments.

Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.

"The new guidelines recognises that excess weight is a long-term condition that can be treated with holistic and lifelong treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and supply-chain constraints are major barriers to widespread availability to the injections that can help people shift significant body mass, notes the body.

GLP-1 Therapy Supply Crisis

Even under the present best projected scenario, the production of these medications might only reach about 100 million people – fewer than 10% of eligible patients, per the health organization.

The recommendation urges nations and manufacturers to widen access, by approaches such as voluntary licensing.

The intellectual property rights on a key compound – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.

How Obesity Injections Work

GLP-1 drugs mimick a natural hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so people consume fewer calories.

Patients typically see weight reduction within a few weeks of beginning the regular doses.

Evidence points to users may regain a significant portion within a year of discontinuing the medication, because their normal food cravings resume.

Being overweight or obese raises your likelihood for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.

Obesity impacts people in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.